Eugene

[email protected]

LATEST

Novartis, Amazon Partner for AI To Improve Mfg, Supply-Chain Systems
By

By
Novartis and Amazon Web Services (AWS), an Amazon.com company, have formed a multi-year strategic collaboration for pharmaceutical manufacturing, supply chain, and delivery operations using AWS’s portfolio of cloud services. Novartis…

Novartis Completes $9.7-Bn Acquisition of The Medicines Company
By

By
Novartis has completed its $9.7-billion acquisition of the Medicines Company, a biopharmaceutical company focused on cardiovascular diseases, through its wholly-owned subsidiary, Medusa Merger Corporation. As a result of the merger,…

Merck & Co., Otsuka Form $2.5-Bn Research and License Pact
By

By
Merck & Co. has formed an exclusive worldwide research collaboration and license agreement, worth up to $2.5 billion with Taiho Pharmaceutical, a subsidiary of Otsuka Holdings, and Astex Pharmaceuticals (UK),…

Global Pharma Briefs: News from Asia, Europe and the US
By

By
A roundup of developments and latest news from China (BI, BeiGene), India (Biocon), Japan (Towa Pharmaceutical, Esteve), Singapore (Tessa Therapeutics), UK (AstraZeneca), and US (Aurobindo, Bausch Health).   China BI…

BMS Divests Italian Mfg Facility to Catalent
By

By
Bristol-Myers Squibb has completed its previously announced divestment of its oral solid, biologics, and sterile-product manufacturing and packaging facility in Anagni, Italy, to Catalent. The Anagni facility manufactures and packages…

Lilly Gains Favorable Ruling in Alimta Patent Litigation
By

By
Eli Lilly and Company reports that a federal district court has ruled in its favor in patent litigation over Alimta (pemetrexed for injection), used to treat certain types of lung…

GSK’s ViiV Healthcare Gets Complete Response Letter from FDA Over Mfg Issues
By

By
ViiV Healthcare, a specialist HIV company majority owned by GlaxoSmithKline, with Pfizer and Shionogi as shareholders, has received a Complete Response Letter (CRL) from the US Food and Drug Administration…

Astellas Acquires Xyphos Biosciences for $665 M
By

By
Astellas Pharma has acquired Xyphos Biosciences, a South San Francisco, California-based company specializing in immuno-oncology products, for $120 million upfront and future development milestones for a total transaction value of…

Glenmark Recalls Lots of Ranitidine
By

By
In another industry recall of ranitidine products, Glenmark Pharmaceutical Inc. USA announced on December 17, 2019, a voluntary recall of all unexpired lots of ranitidine tablets, 150 mg and 300 mg,…

UCB To Invest $336 M in New Biomanufacturing Facility
By

By
UCB has announced that it will build a multi-product biological manufacturing facility on its site in Braine l’Alleud, Wallonia, Belgium. The new biotechnology plant is being constructed to accompany the…